Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca reveals positive results for asthma treatment

AstraZeneca reveals positive results for asthma treatment

10th October 2014

AstraZeneca has unveiled positive safety and efficacy data for its benralizumab asthma treatment.

The novel investigational monoclonal antibody has been identified for use in patients with severe, uncontrolled asthma and elevated volumes of eosinophils – a form of inflammatory white blood cell.

Just last month, the pharmaceutical giant was forced to acknowledge a mid-stage setback in the use of the drug for the treatment of chronic obstructive pulmonary disease (COPD), but this latest positive data has been published in The Lancet medical journal.

Eosinophils is considered to be a trigger for both asthma and COPD and AstraZeneca's MedImmune business has pushed ahead with phase III trials. 

For patients suffering from asthma, benralizumab – an IL-5 antibody – hit its primary endpoint, reducing the rate of exacerbations.

Bing Yao, head of MedImmune's Respiratory, Inflammation and Autoimmunity Innovation unit, said: "Asthma is a highly heterogeneous disease and these data advance our understanding of patient subtypes, potential biomarkers and targeted therapies to achieve the best outcomes for patients."ADNFCR-8000103-ID-801753676-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.